Glenmark Pharma launches anti-diabetes drug Remogliflozin in India
Drug major Glenmark Pharma on Tuesday announced the launch of its anti-diabetes drug Remogliflozin in India. Glenmark is the first company in the wo30-04-2019
30-04-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark launches novel, globally-researched anti-diabetes drug Remogliflozin in India30-04-2019
Glenmark Pharmaceuticals: Back on its feet
Despite corrections in 2017, the stock has bounced back over the last one year28-04-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark receives approval from Russian Ministry of Healthcare to market Momate Rhino metered nasal spray as an Over-the-Counter (OTC) product25-04-2019
Glenmark Pharmaceuticals Ltd - 532296 - Shareholding for the Period Ended March 31, 2019
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here12-04-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 019190 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer09-04-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2019
Enclosed please find herewith the copy of the certificate issued by M/s. Savita Jyoti Associates, Company Secretaries under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 31st March, 201909-04-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2019
Enclosed please find herewith the Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 31st March, 2019.09-04-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Sub: Disclosure under Regulation 8(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015 We wish to inform you that the Board of Directors has amended Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information ('the Code') to align it with the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018. In compliance with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, we are enclosing herewith the amended Code for your record. The Code is also available on the website of the Company at www.glenmarkpharma.com28-03-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Change in Management
Sub: Intimation of Appointment of Ms. Sona Saira Ramasastry (DIN-0008398547) as an Additional Director - Independent Director Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), we are pleased to inform that on recommendation of Nomination & Remuneration Committee, the Board has appointed Ms. Saira as an Additional Director to hold office as an Independent Director of the Company for a term of Five years with effect from 1st April, 2019, not liable to retire by rotation, subject to the approval of the shareholders at the ensuing General Meeting. Ms. Saira is not debarred from holding the office of director by virtue of any order passed by SEBI or any other authority. Accordingly, please find enclosed the requisite information as required under SEBI Circular dated 9th September, 2015 content of which is self-explanatory.28-03-2019